Table 3.

PROMISE analysis identified genes change in expression post ara-C to be predictive of beneficial or detrimental patterns of association with clinical endpoints in AML patients [q<0.3]

A. PROMISE 3 [PR3] analysis utilizing 3 endpoints LC50, MRD22 and EFS
ProbelD	Gene Symbol	LC50. stat	MRD22. stat	EFS. stat	PROMIS E. stat	LC50 p value	MRD22 p value	EFS p value	PR3 p value	BH95_q	PC06_q	Risk p value
201088_at	KPNA2	0.708	0.568	0.290	−0.522	0.044	0.006	0.136	0.000	0.000	0.000	0.171
203699_s_at	DIO2	−0.708	−0.468	−0.506	0.561	0.040	0.026	0.009	0.000	0.000	0.000	0.472
205547_s_at	TAGLN	−0.773	−0.462	−0.447	0.561	0.030	0.026	0.020	0.000	0.000	0.000	0.662
205569_at	LAMP3	−0.773	−0.406	−0.614	0.598	0.028	0.060	0.001	0.000	0.000	0.000	0.686
206160_at	APOBEC2	−0.602	−0.531	−0.493	0.542	0.110	0.010	0.010	0.000	0.000	0.000	0.245
207366_at	KCNS1	−0.773	−0.365	−0.448	0.529	0.024	0.085	0.020	0.000	0.000	0.000	0.879
209668_x_at	CES2	−0.773	−0.537	−0.253	0.521	0.030	0.008	0.203	0.000	0.000	0.000	0.658
210119_at	KCNJ15	−0.773	−0.586	−0.331	0.564	0.027	0.004	0.090	0.000	0.000	0.000	0.531
220849_at	FLJ22659	−0.838	−0.291	−0.549	0.559	0.007	0.177	0.004	0.000	0.000	0.000	0.719
221793_at	DOCK6	−0.708	−0.400	−0.650	0.586	0.043	0.064	0.000	0.000	0.000	0.000	0.886
201053_s_at	PSMF1	0.773	0.403	0.306	−0.494	0.027	0.057	0.116	0.000	0.153	0.118	0.842
205444_at	ATP2A1	−0.773	−0.523	−0.349	0.548	0.029	0.011	0.071	0.000	0.153	0.118	0.259
207780_at	CYLC2	−0.708	−0.435	−0.460	0.534	0.042	0.041	0.017	0.000	0.153	0.118	0.858
212436_at	TRIM33	−0.602	−0.478	−0.668	0.583	0.116	0.024	0.000	0.000	0.153	0.118	0.983
216708_x_at	IGL2	−0.643	−0.520	−0.411	0.525	0.096	0.013	0.033	0.000	0.153	0.118	0.638
217330_at	DISC1	−0.643	−0.307	−0.607	0.519	0.097	0.152	0.001	0.000	0.153	0.118	0.284
221999_at	VRK3	−0.838	−0.504	−0.233	0.525	0.008	0.017	0.246	0.000	0.153	0.118	0.388
38447_at	ADRBK1	−0.643	−0.400	−0.546	0.530	0.091	0.059	0.003	0.000	0.153	0.118	0.809
208429_x_at	HNF4A	−0.659	−0.277	−0.549	0.495	0.066	0.200	0.004	0.000	0.217	0.192	0.854
211920_at	CFB	−0.643	−0.450	−0.408	0.500	0.097	0.031	0.032	0.000	0.217	0.192	0.943
214598_at	CLDN8	−0.708	−0.579	−0.309	0.532	0.043	0.004	0.114	0.000	0.217	0.192	0.435
217857_s_at	RBM8A	0.708	0.325	0.530	−0.521	0.042	0.133	0.005	0.000	0.217	0.192	0.476
202585_s_at	NFX1	−0.773	−0.326	−0.427	0.509	0.027	0.132	0.028	0.000	0.278	0.254	0.941
209966_x_at	ESRRG	−0.667	−0.417	−0.472	0.519	0.050	0.049	0.013	0.000	0.278	0.254	0.355
213078_x_at	AGPAT7	−0.838	−0.291	−0.372	0.500	0.008	0.172	0.052	0.000	0.278	0.254	0.498

B. PROMISE 2 [PR2] analysis utilizing 2 clinical endpoints [MRD22 and EFS]
ProbelD	Gene. Symbol	MRD22. stat	EFS. stat	PROMI SE. stat	MRD22 p value	EFS p value	PR2 p value	BH95_q	PC06_q	Risk p value
221212_x_at	PB1	−0.613	−0.635	0.624	0.003	0.001	0.000	0.000	0.000	0.212
221365_at	MLNR	−0.611	−0.529	0.570	0.002	0.004	0.000	0.000	0.000	0.284